1197-18-8
- Product Name：Tranexamic acid
- Molecular Formula：C8H15NO2
- Purity：99%
- Molecular Weight：
Product Details
Appearance:white crystalline powder
High Purity Tranexamic acid 1197-18-8 for sale, Good Supplier In China
- Molecular Formula:C8H15NO2
- Molecular Weight:157.213
- Appearance/Colour:white crystalline powder
- Vapor Pressure:0mmHg at 25°C
- Melting Point:300 °C
- Refractive Index:1.497
- Boiling Point:300.201 °C at 760 mmHg
- PKA:pKa 4.3 (Uncertain);10.6 (Uncertain)
- Flash Point:135.357 °C
- PSA：63.32000
- Density:1.096 g/cm3
- LogP:1.53640
Tranexamic acid 1197-18-8 Usage
Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether. The use of tranexamic acid (TXA) is associated with less blood loss and reduced transfusion risk after shoulder arthroplasty surgery. Tranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.
Clinical Use
Haemostatic agent
Synthesis
Tranexamic acid, trans-4-(aminomethyl)cyclohexane carboxylic acid (24.4.5), is synthesized from 4-methylbenzonitrile.
Drug interactions
Potentially hazardous interactions with other drugs None known
Metabolism
Tranexamic acid is excreted as unchanged drug mainly by urinary excretion via glomerular filtration.
InChI:InChI=1/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
1197-18-8 Relevant articles
The effect of intravenous unit-dose tranexamic acid on visible and hidden blood loss in posterior lumbar interbody fusion: a randomized clinical trial
Shenshen Hao, Hongke Li, Shuai Liu, Saike Meng, Xiaopeng Zhang, Linfei Wang, Hongjie Yang, Liyan Zhang & Shengli Dong
Scientific Reports volume 13, Article number: 4714 (2023)
Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that inhibits plasminogen, fibrinolysis and tissue plasminogen activator binding by competing for lysine binding sites. Thereby delaying fibrinolysis and blood clot degradation, TXA achieves the purpose of reducing intraoperative bleeding.
Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery
Luis D. Pacheco, M.D., Rebecca G. Clifton, Ph.D., George R. Saade, M.D., Steven J. Weiner, M.S., Samuel Parry, M.D., John M. Thorp, Jr., M.D., Monica Longo, M.D., Ph.D., Ashley Salazar, R.N., M.S.N., W.H.N.P., Wendy Dalton, R.N., Alan T.N. Tita, M.D., Ph.D., Cynthia Gyamfi-Bannerman, M.D., Suneet P. Chauhan, M.D., Torri D. Metz, M.D., Kara Rood, M.D., Dwight J. Rouse, M.D., Jennifer L. Bailit, M.D., M.P.H., William A. Grobman, M.D., Hyagriv N. Simhan, M.D., and George A. Macones, M.D
April 13, 2023 N Engl J Med 2023; 388:1365-1375
A total of 11,000 participants underwent randomization (5529 to the tranexamic acid group and 5471 to the placebo group); scheduled cesarean delivery accounted for 50.1% and 49.2% of the deliveries in the respective groups.
Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis
GD Leverett, A Marriott
Orthopaedics & Traumatology: Surgery & Research Volume 109, Issue 2, April 2023, 103337
Despite the demonstrated safety of tranexamic acid (TXA) in elective hip arthroplasty, there is uncertainty regarding the risk of thromboembolism with the administration of TXA during hip fracture surgery.
1197-18-8 Process route
-
- 1197-17-7,1197-18-8,701-54-2
4-aminomethyl-cyclohexanecarboxylic acid
| Conditions | Yield |
|---|---|
|
|
|
|
|
|
|
|
-
- 953817-12-4
C12H17NO5
-
- 108-31-6
maleic anhydride
-
- 1197-18-8
trans-4-aminomethyl-cyclohexyl-carboxylic acid
| Conditions | Yield |
|---|---|
|
With hydrogenchloride; In water; for 1h; Kinetics;
|
1197-18-8 Upstream products
-
15177-68-1
trans-4-cyanocyclohexane-1-ylcarboxylic acid
-
19145-95-0
methyl trans-4-cyanocyclohexane-1-carboxylate
-
953817-12-4
C12H17NO5
-
1129-35-7
4-cyanobenzoic acid methyl ester
1197-18-8 Downstream products
-
41931-38-8
4-(5-benzyl-6-thioxo-[1,3,5]thiadiazinan-3-ylmethyl)-cyclohexanecarboxylic acid
-
23199-14-6
4-aminomethyl-cyclohexanecarboxylic acid methyl ester
-
102196-03-2
methyl 3-
-
927869-66-7
4-((2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-7-sulfonamido)methyl)cyclohexanecarboxylic acid
Relevant Products
-
Cyclopropane, isocyanato- 4747-72-2CAS：4747-72-2
-
VanillinCAS：121-33-5
-
Chlorpheniramine maleateCAS：113-92-8
